Search results for "InVEST"

showing 10 items of 2596 documents

Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT…

2021

Abstract Background Embryonal tumors with multilayered rosettes (ETMR) are highly aggressive tumors occurring in early childhood. Published clinical data refer to retrospective, heterogeneously treated cohorts. Here, we describe the outcome of patients treated according to the prospective P-HIT trial and subsequent HIT2000-interim-registry. Patients and methods Age-stratified treatment included carboplatin/etoposide induction, tandem high-dose chemotherapy (“CARBO/ETO + HDCT”), and response-stratified radiotherapy. Patients with centrally reviewed neuropathological and molecularly confirmed diagnosis of ETMR recruited within the P-HIT trial (2001-2011; n = 19), the HIT2000-interim-registry …

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentMedizinClinical InvestigationsImproved survival610 Medicine & healthBrain Neoplasms/drug therapyCentral Nervous System NeoplasmsHigh dose chemotherapychemistry.chemical_compoundCarboplatin/therapeutic useInternal medicinemedicineHigh-dose chemotherapyHumansNeuroectodermal Tumors Primitive1306 Cancer ResearchProspective StudiesChildOutcomeEtoposideRetrospective StudiesChemotherapyddc:618business.industryBrain NeoplasmsIncidence (epidemiology)IncidenceInfantInduction ChemotherapyNeoplasms Germ Cell and EmbryonalCarboplatinETMRRadiation therapyClinical trialClinical trial2728 Neurology (clinical)Oncologychemistry10036 Medical ClinicChild Preschool2730 OncologyNeurology (clinical)Antineoplastic Combined Chemotherapy Protocols/therapeutic usebusinessCarboplatin/etoposideNeoplasms Germ Cell and Embryonal/drug therapy
researchProduct

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

2021

Abstract Objectives The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non‐small cell lung cancer (NSCLC) patients treated with first‐ or second‐generation EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs). Another goal was to monitor the dynamics of EGFR mutations, as well as to track EGFR exon 20 p.T790M (p.T790M) resistance during treatment, as critical indicators of therapeutic efficacy and patient survival. Methods Stage IV NSCLC patients with locally confirmed EGFR‐TKI sensitizing mutations (ex19del and/or L858R) in biopsy tissue who were candidates to…

OncologyMaleCancer ResearchPulmons - Càncer - PrognosiLung Neoplasms:técnicas de investigación::técnicas genéticas::análisis de secuencias::análisis de secuencias de ADN::análisis de mutaciones del ADN [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]medicine.disease_causeBEAMingExonnon-small cell lung carcinomaInterquartile rangeCarcinoma Non-Small-Cell LungEpidermal growth factor receptorProspective StudiesRC254-282Research ArticlesMutationmedicine.diagnostic_testbiologyHazard ratioNeoplasms. Tumors. Oncology. Including cancer and carcinogens:Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma Bronchogenic::Carcinoma Non-Small-Cell Lung [DISEASES]ErbB ReceptorsOncology:Investigative Techniques::Genetic Techniques::Sequence Analysis::Sequence Analysis DNA::DNA Mutational Analysis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]FemaleADN - AnàlisiResearch Articlemedicine.medical_specialty:Otros calificadores::/diagnóstico [Otros calificadores]Internal medicineBiopsymedicineHumansRadiology Nuclear Medicine and imagingLiquid biopsyAgedliquid biopsybusiness.industryClinical Cancer Research:neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES]EGFR mutationsConfidence intervalnon‐small cell lung carcinomarespiratory tract diseases:Neoplasms [DISEASES]Mutationbiology.proteinbusinessPulmons - Càncer - Tractament
researchProduct

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIO…

2013

BackgroundThis multicenter phase II study investigated temozolomide + irinotecan (TEMIRI) treatment in children with relapsed or refractory medulloblastoma.MethodsPatients received temozolomide 100–125 mg/m2/day (days 1–5) and irinotecan 10 mg/m2/day (days 1–5 and 8–12) every 3 weeks. The primary endpoint was tumor response within the first 4 cycles confirmed ≥4 weeks and assessed by an external response review committee (ERRC). In a 2-stage Optimum Simon design, ≥6 responses in the first 15 evaluable patients were required within the first 4 cycles for continued enrollment; a total of 19 responses from the first 46 evaluable patients was considered successful.ResultsSixty-six patients were…

OncologyMaleCancer Researchmedicine.medical_specialtyAdolescentmedicine.medical_treatmentClinical InvestigationsPhases of clinical researchtemozolomideNeutropeniaIrinotecanmedulloblastomaTEMIRIInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansCerebellar NeoplasmsChildChemotherapyTemozolomidebusiness.industrymedicine.diseaseChemotherapy regimenSurgeryIrinotecanDacarbazineOncologyTolerabilityChild PreschoolCamptothecinFemaleNeurology (clinical)businessmedicine.drug
researchProduct

Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials

2005

In the last two decades the results of medical treatment of advanced non-small cell lung cancer (NSCLC) have constantly improved even if they are still far from being considered satisfactory. Today systemic cisplatin-based chemotherapy (CT) is able to increase survival and improve cancer-related symptoms in patients with advanced ‘wet’ stage III and metastatic stage IV NSCLC, but it not clear if the benefits of CT also apply to patients with poor performance status (PS) [1, 2]. PS is the most powerful independent prognostic factor in advanced NSCLC since it is a reliable measure of functional independence, ability to perform daily activities and work, and a strong predictor of survival and …

Oncologymedicine.medical_specialtyLung Neoplasmsbusiness.industryDrugs Investigationallung cancer performance status 2 chemotherapy best supportive careHematologymedicine.diseaseClinical trialRegimenOncologyQuality of lifeCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansControlled Clinical Trials as TopicStage (cooking)Lung cancerbusinessAdverse effectSurvival rateSurvival analysisNeoplasm StagingAnnals of Oncology
researchProduct

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

2010

Background: Drug development traditionally has relied upon the complementary contributions of clinicians and scientists at academic institutions and at pharmaceutical companies. Greater regulatory burdens, increased bureaucratic requirements, restricted reimbursement, and spiralling research and development costs are exerting pressure on the drug development pipeline. The result is a de-emphasis of exploratory research, particularly independent academic research, despite its proven value in identifying new drug targets and developing innovative cancer therapies. Design: An expert panel assembled by the Biotherapy Development Association-a nonprofit international forum for academic and indus…

Oncologymedicine.medical_specialtyacademic research Clinical Trials Directive drug development investigator-initiated trials oncologytargeted therapiesSettore MED/06 - Oncologia MedicaeducationExploratory researchReviewsAntineoplastic AgentsPatient advocacyInternal medicineNeoplasmsmedicineHumanshealth care economics and organizationsReimbursementLicensureGovernmentClinical Trials as Topicbusiness.industryLegislatureHematologyResearch PersonnelClinical trialOncologyDrug developmentbusinessAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

2021

Chronic myeloid leukemia; BCR-ABL1 transcripts; Response to imatinib Leucemia mieloide crónica; Transcripciones de BCR-ABL1; Respuesta al imatinib Leucèmia mieloide crònica; Transcripcions BCR-ABL1; Resposta a imatinib The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics, cumulative cytogenetic and molecular responses to IM, acquisition of deep molecular response …

Oncologymedicine.medical_specialtyrelapse-free survivalLeucèmia mieloide<i>BCR</i><i>-ABL1</i> transcriptsLeucèmia mieloide crònica:Organic Chemicals::Amides::Benzamides::Imatinib Mesylate [CHEMICALS AND DRUGS]survivalArticleOncología:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myelogenous Chronic BCR-ABL Positive [DISEASES]03 medical and health sciencesBcr abl10302 clinical medicineAnàlisi de supervivència (Biometria)chronic myeloid leukemiaInternal medicinehemic and lymphatic diseasesresponse to imatinibmedicineOverall survivalHematologíaCumulative incidenceBCR-ABL1 transcriptsGene transcriptbusiness.industryRMyeloid leukemiaImatinibGeneral MedicineExpressió gènica:técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Myeloid leukemia030220 oncology & carcinogenesisMolecular ResponseImatinib:compuestos orgánicos::amidas::benzamidas::mesilato de imatinib [COMPUESTOS QUÍMICOS Y DROGAS]MedicineRemission rateGene expression:Health Care Quality Access and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Statistics as Topic::Survival Analysis [HEALTH CARE]business:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES]030215 immunologymedicine.drugdiscontinuation
researchProduct

Datos abiertos de investigación. Camino recorrido y cuestiones pendientes

2017

[ES]: Los aspectos profesionales y técnicos de la gestión de datos de investigación han avanzado, por ejemplo las infraestructuras tecnológicas o los esquemas de metadatos de descripción. Sin embargo, otras cuestiones siguen necesitando ser investigadas, y más ahora en que los datos han de estar disponibles en abierto. Este trabajo efectúa una revisión bibliográfica y de sitios web de referencia que permite identificar los últimos avances producidos y las tendencias de investigación en temas relacionados con los datos científicos. La publicación de datos en revistas, el estudio del comportamiento de los autores o los métodos para medir el impacto de los datos son aspectos que necesitan ser …

Open datalcsh:Information resources (General)Investigación científicaBIBLIOTECONOMIA Y DOCUMENTACIONMétodos de investigaciónDatos abiertosLibrary and Information SciencesScientific researchResearch data:0 - Generalidades.::02 - Biblioteconomía. Documentación [CDU]InvestigacióDatos de investigaciónResearch methodslcsh:ZA3040-5185Anales de Documentación
researchProduct

Forecasting Adverse Weather Situations in the Road Network

2016

Weather is an important factor that affects traffic flow and road safety. Adverse weather situations affect the driving conditions directly; hence, drivers must be informed about the weather conditions downstream to adapt their driving. In the framework of intelligent transport systems, several systems have been developed to know the weather situations and inform drivers. However, these systems do not forecast weather in advance, and they need the support of road operators to inform drivers. This paper presents a new autonomous system to forecast weather conditions in a short time and to give users the information obtained. The system uses a set of algorithms and rules to determine the weat…

Operations researchComputer sciencemedia_common.quotation_subjectTransport per carreteraexpert systems02 engineering and technologyInvestigació0502 economics and business0202 electrical engineering electronic engineering information engineeringRoad Weather Information SystemQuality (business)MeteorologiaSet (psychology)Intelligent transportation systemDownstream (networking)media_commonintelligent transport systems (ITS)050210 logistics & transportationAdverse weatherSeguretat viàriaMechanical Engineeringmultiagent system05 social sciencesTraffic flowComputer Science ApplicationsAutomotive EngineeringAccidents Prevenció020201 artificial intelligence & image processingAutonomous system (mathematics)
researchProduct

Nosotros, también con Garzón

2009

OposiciónDemocraciaConvención de GinebraVidal-Beneyto JoséManos limpiasGarzónJusticia democráticaVerdugosFranquismoCrímenes del franquismoDerechos HumanosReparaciónPasadoESPAÑAJusticiaEspectáculoMEMORIA DEMOCRÁTICAInvestigaciónNaciones UnidasJudicaturaJuecesMemoria históricaPublicaciones: Obra periodística: Cartas al director
researchProduct